| scholarly article | Q13442814 |
| P2093 | author name string | Stefani Spranger | |
| Thomas F Gajewski | |||
| P2860 | cites work | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis | Q24658222 | ||
| Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine | Q26748727 | ||
| MYC, Metabolism, and Cancer | Q26783555 | ||
| Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity | Q27489852 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells | Q28248489 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells | Q28591976 | ||
| NF-kappaB functions as a tumour promoter in inflammation-associated cancer | Q29614598 | ||
| IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer | Q29614599 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice | Q29615615 | ||
| Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas | Q29616243 | ||
| The LKB1-AMPK pathway: metabolism and growth control in tumour suppression | Q29617506 | ||
| MYC on the path to cancer | Q29619979 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 | ||
| LKB1 modulates lung cancer differentiation and metastasis | Q30080027 | ||
| Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment | Q30415355 | ||
| Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment | Q33606150 | ||
| Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors | Q33765767 | ||
| CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation | Q34346803 | ||
| Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma | Q34478015 | ||
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Q34522172 | ||
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 | ||
| Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity | Q34625640 | ||
| Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas | Q35008028 | ||
| Cross-presentation of tumor associated antigens through tumor-derived autophagosomes | Q35084414 | ||
| STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. | Q35263440 | ||
| β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas | Q35621787 | ||
| Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity | Q35634752 | ||
| Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. | Q35737352 | ||
| Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy | Q35833912 | ||
| Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota | Q35833921 | ||
| Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation | Q35928960 | ||
| Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. | Q36134167 | ||
| Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints | Q36160526 | ||
| The consensus molecular subtypes of colorectal cancer | Q36258187 | ||
| Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. | Q36553576 | ||
| Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression | Q36637905 | ||
| Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy | Q36653748 | ||
| Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma | Q36730827 | ||
| Molecular and genetic properties of tumors associated with local immune cytolytic activity | Q36869059 | ||
| Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects | Q37077185 | ||
| NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells | Q37191112 | ||
| p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells | Q37194949 | ||
| Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma | Q37222679 | ||
| Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma | Q37428076 | ||
| Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma | Q37473978 | ||
| Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors | Q37474092 | ||
| STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. | Q37502349 | ||
| Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas | Q37730613 | ||
| Regulation of cell death and autophagy by IKK and NF-κB: critical mechanisms in immune function and cancer | Q37995693 | ||
| STAT3 activation: A key factor in tumor immunoescape | Q38140901 | ||
| Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy | Q38704192 | ||
| IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. | Q38709131 | ||
| STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. | Q38731119 | ||
| Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy | Q38743794 | ||
| Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. | Q38776860 | ||
| Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment | Q38779257 | ||
| MYC regulates the antitumor immune response through CD47 and PD-L1 | Q38787131 | ||
| Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy | Q39130451 | ||
| Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. | Q39338105 | ||
| Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors | Q39379480 | ||
| Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 | ||
| Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. | Q40050674 | ||
| Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients | Q40241105 | ||
| Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells | Q40602668 | ||
| Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability | Q40850728 | ||
| Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity | Q40944056 | ||
| Claudin-low bladder tumors are immune infiltrated and actively immune suppressed | Q41160701 | ||
| Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. | Q41571576 | ||
| Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer | Q42176800 | ||
| Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia | Q42521880 | ||
| Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer | Q47782346 | ||
| Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling. | Q47962756 | ||
| PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses | Q48008350 | ||
| Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. | Q48173597 | ||
| The spectrum of T cell metabolism in health and disease | Q49853005 | ||
| An immune-active tumor microenvironment favors clinical response to ipilimumab | Q56898024 | ||
| Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy | Q56965582 | ||
| Enhancing Chemotherapy Efficacy in Pten -Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity | Q63884125 | ||
| Sustained loss of a neoplastic phenotype by brief inactivation of MYC | Q74413944 | ||
| On the TRAIL toward death receptor-based cancer therapeutics | Q80117652 | ||
| Characterization of melanocyte-specific inducible Cre recombinase transgenic mice | Q83290390 | ||
| Targeting neoantigens to augment antitumour immunity | Q88839268 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 139-147 | |
| P577 | publication date | 2018-01-12 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | Impact of oncogenic pathways on evasion of antitumour immune responses | |
| P478 | volume | 18 |
| Q92072042 | Allies or Enemies-The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment |
| Q90142120 | Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma |
| Q58104267 | Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects |
| Q91658442 | BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine |
| Q89206309 | Beyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors Via CDK4/6 Inhibition |
| Q60919588 | Bioactive Nanoparticles for Cancer Immunotherapy |
| Q92310063 | Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors |
| Q93162228 | Cancer stemness, intratumoral heterogeneity, and immune response across cancers |
| Q90690121 | Characterization of human cancer xenografts in humanized mice |
| Q89793689 | Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment |
| Q99551100 | Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer |
| Q59798138 | Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy |
| Q92578527 | Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy |
| Q101226463 | De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors |
| Q89944648 | Determinants of Resistance to Checkpoint Inhibitors |
| Q60947640 | Dissecting the Immune Landscape of Acute Myeloid Leukemia |
| Q92723030 | Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response |
| Q91942447 | Dual Pro- and Anti-Inflammatory Features of Monocyte-Derived Dendritic Cells |
| Q90669058 | Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells |
| Q90482442 | Exercise Training in Cancer Control and Treatment |
| Q93043610 | Firing Up Cold Tumors |
| Q92014001 | Genetic Programs Driving Oncogenic Transformation: Lessons from in Vitro Models |
| Q98183420 | Genetic and epigenetic regulation of cancer coagulome - lessons from heterogeneity of cancer cell populations |
| Q98906809 | Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer |
| Q92179996 | Genomic correlates of response to immune checkpoint blockade |
| Q64086837 | Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective |
| Q92341987 | Host tissue determinants of tumour immunity |
| Q90569691 | Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade |
| Q90628298 | Identification of Antigenic Targets |
| Q57791813 | Immune Evasion, a Potential Mechanism of Trichothecenes: New Insights into Negative Immune Regulations |
| Q97528619 | Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations |
| Q52804400 | Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets. |
| Q94452370 | Immunomodulation by anticancer cell cycle inhibitors |
| Q58550797 | Immunotherapy failure in adrenocortical cancer: where next? |
| Q93162619 | Improving cancer immunotherapy through nanotechnology |
| Q104135062 | Influenza virus neuraminidase regulates host CD8+ T-cell response in mice |
| Q64883630 | Integrating the DNA damage and protein stress responses during cancer development and treatment. |
| Q100992474 | Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells |
| Q89620002 | Leukobiopsy - A Possible New Liquid Biopsy Platform for Detecting Oncogenic Mutations |
| Q104745191 | Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination |
| Q92586096 | Making cold malignant pleural effusions hot: driving novel immunotherapies |
| Q56886821 | Mechanisms of Resistance to Immune Checkpoint Blockade |
| Q100737293 | Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state |
| Q64095218 | Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma |
| Q57818011 | Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology |
| Q57395724 | Natural killer cells and other innate lymphoid cells in cancer |
| Q90349565 | Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis |
| Q98776115 | Onodera's prognostic nutritional index correlates with tumor immune environment and survival in patients with oral squamous cell carcinoma undergoing chemoradiotherapy |
| Q92334728 | Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy |
| Q92094127 | Overcoming Wnt-β-catenin dependent anticancer therapy resistance in leukaemia stem cells |
| Q92541764 | Ping-Pong-Tumor and Host in Pancreatic Cancer Progression |
| Q63246478 | Potential Therapies for Infectious Diseases Based on Targeting Immune Evasion Mechanisms That Pathogens Have in Common With Cancer Cells |
| Q58769285 | Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification |
| Q90568070 | Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer |
| Q56888903 | RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade |
| Q91297827 | Regulatory T cells in cancer immunosuppression - implications for anticancer therapy |
| Q91422883 | Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma |
| Q97520423 | Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies |
| Q57296955 | Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity |
| Q64946390 | Role of p53 in the Regulation of the Inflammatory Tumor Microenvironment and Tumor Suppression. |
| Q54213148 | Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations. |
| Q92245345 | T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance |
| Q92350765 | Tankyrase inhibition sensitizes cells to CDK4 blockade |
| Q93216930 | Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models |
| Q91974682 | Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment |
| Q98166041 | Targeting regulatory T cells for improving cancer therapy: Challenges and prospects |
| Q90677037 | The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier |
| Q54122937 | The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? |
| Q92083224 | The Vicious Cross-Talk between Tumor Cells with an EMT Phenotype and Cells of the Immune System |
| Q90242165 | The emerging role of epigenetic therapeutics in immuno-oncology |
| Q90372098 | The lung microenvironment: an important regulator of tumour growth and metastasis |
| Q97525228 | Toward Systems Biomarkers of Response to Immune Checkpoint Blockers |
| Q90265999 | Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology |
| Q92511116 | Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2) |
| Q89454298 | Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells |
| Q92173942 | Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features |
| Q90391286 | Tumour-intrinsic resistance to immune checkpoint blockade |
| Q96945876 | Turning Cold into Hot: Firing up the Tumor Microenvironment |
| Q62766311 | Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle |
| Q56888915 | WNT Signaling in Cancer Immunosurveillance |
| Q92538517 | WNT Signaling in Tumors: The Way to Evade Drugs and Immunity |
| Q90733181 | WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment |
| Q64104154 | Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma |
| Q98281070 | Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer |
| Q64893136 | m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. |
| Q99558042 | β-Catenin inhibition shapes tumor immunity and synergizes with immunotherapy in colorectal cancer |
Search more.